Pipeline

We turn science into medicine

Our appreciation for, and understanding of, the power of the human immune system gives us a unique perspective on how to respond to the constant challenges of oncology drug development. We use our expertise to produce innovative antibody-based therapeutics that have the potential to transform cancer treatment.

We are proud to have three Genmab-created products on the market by our collaborators. We also have a pipeline of antibody therapeutics that includes products in clinical development, and in-house and partnered pre-clinical programs.

products

Our groundbreaking accomplishments

  • 3

    Marketed products created by Genmab*

  • 4

    Proprietary Genmab technologies

  • 20

    Genmab created products in clinical development

  • ~20

    In-house and partnered pre-clinical programs

Products in development


At Genmab, we are inspired by nature and understand how antibodies work. We are proud to invest in and advance a robust pipeline of differentiated product candidates that are at the forefront of the industry. This is accomplished by leveraging our own cutting-edge scientific capabilities, innovative scientific approach, translational medicine laboratory expertise and strategic partnerships. 

Our deep scientific understanding of our antibody products, including which patients will benefit most from them, will help to define Genmab as an oncology leader.

Filters

Product Pipeline

Products created by Genmab*

  • Daratumumab

    Partnership: Janssen Biotech, Inc.

    Target: CD38

    Multiple myeloma:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    AL Amyloidosis:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Non-MM blood cancers:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Daratumumab is a human IgG1k monoclonal antibody (mAb) that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of multiple myeloma cells.1 Daratumumab is being developed by Janssen Biotech, Inc. under an exclusive worldwide license to develop, manufacture and commercialize daratumumab from Genmab.

    A subcutaneous formulation of daratumumab, DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) has been approved by the U.S. FDA for certain multiple myeloma indications.

    Indication and Safety

    Daratumumab, marketed as DARZALEX®, is the first human CD38 monoclonal antibody to reach the market and the first monoclonal antibody (mAb) to receive the U.S. Food and Drug Administration (U.S. FDA) approval to treat multiple myeloma.

    In the U.S., side effects may be reported to the FDA at 1-800-FDA-1088. Patients in the U.S., E.U. and Japan can also contact the local Janssen Drug Safety Team about reporting side effects.

    Clinical Studies

    A comprehensive clinical development program for daratumumab is ongoing by Janssen.

    Reference

    1. De Weers, M et al. Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors. J Immunol. 2011;186:1840-1848.

    More info

  • Ofatumumab

    Partnership: Novartis Pharma AG.

    Target: CD20

    Chronic lymphocytic leukemia:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops.

    Indication and Safety

    Ofatumumab is approved as Arzerra® in certain territories to treat certain chronic lymphocytic leukemia (CLL) indications.

    To report suspected adverse reactions in the U.S., contact Novartis Pharmaceuticals Corporation at 1-888-669-6682 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

    More info

  • Teprotumumab

    Partnership: Horizon, under a license from Roche

    Target: IGF-1R

    Thyroid eye disease:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Teprotumumab is a fully human antibody created by Genmab under a collaboration with Roche.

    Indication and Safety

    The U.S. FDA approved teprotumumab-trbw as TEPEZZA® for the treatment of thyroid eye disease (TED).

    To report an Adverse Event or Side Effect, Horizon requests patients contact 1-866-479-6742 {Option 1} or visit www.fda.gov/medwatch or call 1-800-FDA-1088.

    More info

Genmab proprietary products

  • Tisotumab vedotin

    Partnership: Seattle Genetics, Inc.

    Target: Tissue Factor

    Cervical cancer:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Ovarian cancer:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Tisotumab vedotin is an antibody-drug conjugate (ADC) targeted to tissue factor (TF), a protein involved in tumor signaling and angiogenesis.1 It is composed of Genmab’s human monoclonal antibody (mAb) that binds to TF and Seattle Genetics, Inc.’s ADC technology that utilizes a cleavable linker and the cytotoxic drug monomethyl auristatin E (MMAE).1 TF is a transmembrane protein that is the main physiological initiator of coagulation and is involved in angiogenesis, cell adhesion, motility, and cell survival.2,3 The presence of TF is associated with poor prognosis.1

    Clinical Trials

    Tisotumab vedotin is being tested in clinical studies in a variety of solid tumors.4

    References

    1. Breij ECW, de Goeij BECG, Verploegen S, et al. An antibody-drug conjugate that targets tissue factor exhibits potent therapeutic activity against a broad range of solid tumors. Cancer Res. 2014;74(4):1214-1226.
    2. Chu AJ. Tissue factor, blood coagulation, and beyond: an overview. Int J Inflam. 2011;2011:36784. doi:10.4061/2011/367284.
    3. Ruf W. Tissue factor and cancer. Thromb Res. 2012;130:S84-S87.
    4. US National Institutes of Health. Tisotumab vedotin continued treatment in patients with solid tumors. https://clinicaltrials.gov/ct2/show/NCT03245736?term=tisotumab+vedotin&rank=1 Updated August 10, 2017. Accessed March 14, 2018.

    More info

  • Enapotamab vedotin

    Partnership: 

    Target: AXL

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Enapotamab vedotin is an antibody-drug conjugate (ADC) targeted to AXL. AXL is a unique receptor tyrosine kinase (RTK) that is aberrantly expressed in many solid tumor types and is implicated in tumor cell proliferation, migration, and invasion.1 Enapotamab vedotin is fully owned by Genmab, and the ADC technology is licensed from Seattle Genetics.

    Clinical Trials

    A Phase 1/2 study is currently ongoing in a variety of solid tumors.2

    References

    1. Song X, Wang H, Logsdon CD, et al. Overexpression of receptor tyrosine kinase Axl promotes tumor cell invasion and survival in pancreatic ductal adenocarcinoma. Cancer. 2011;117(4):734-743.
    2. US National Institutes of Health. HuMax®-AXL-ADC safety study in patients with solid tumors. https://clinicaltrials.gov/ct2/show/NCT02988817?term=genmab+axl&rank=1 Updated August 16, 2017. Accessed March 14, 2018.

    More info

  • HexaBody®-DR5/DR5

    Partnership: 

    Target: DR5

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    HexaBody®-DR5/DR5 (GEN1029) is a mixture of two non-competing HexaBody® molecules that target two distinct epitopes on death receptor 5 (DR5), a cell surface receptor that mediates programmed cell death. Increased expression of DR5 has been reported in several types of tumors. HexaBody®-DR5/DR5 is the first HexaBody® molecule to enter the clinic.

    Clinical Studies

    A Phase 1/2 study is currently ongoing in a variety of solid tumors.

    More info

  • Epcoritamab (DuoBody®-CD3xCD20)

    Partnership: AbbVie

    Target: CD3, CD20

    Hematological malignancies:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Epcoritamab (DuoBody®-CD3xCD20) is a proprietary bispecific antibody created using Genmab’s DuoBody® technology, jointly owned by Genmab and AbbVie. It targets CD20 on the B-cells, a clinically well-validated target that is expressed in a wide variety of B-cell malignancies.

    Clinical Trials

    Epcoritamab (DuoBody®-CD3xCD20) is currently under investigation in a Phase 1/2 study for multiple hematological B-cell malignancies.

    More info

  • DuoBody®-PD-L1x4-1BB (GEN1046)

    Partnership: BioNTech

    Target: PD-L1, 4-1BB

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    DuoBody®-PD-L1x4-1BB (GEN1046) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed by Genmab under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. DuoBody®-PD-L1x4-1BB targets PD-L1 and 4-1BB, selected to block inhibitory PD-1/PD-L1 axis and simultaneously activate essential co-stimulatory activity via 4-1BB using inert DuoBody® antibody format.

    Clinical Trials

    A Phase 1/2 clinical study of DuoBody®-PD-L1x4-1BB in solid tumors is ongoing.

    More info

  • DuoBody®-CD40x4-1BB (GEN1042)

    Partnership: BioNTech

    Target: CD40, 4-1BB

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    DuoBody®-CD40x4-1BB (GEN1042) is a proprietary bispecific antibody, jointly owned by Genmab and BioNTech, created using Genmab’s DuoBody® technology. It is being co-developed under an agreement in which the companies share all costs and future profits for the product on a 50:50 basis. CD40 and 4-1BB were selected as targets to enhance both dendritic cells (DC) and antigen-dependent T-cell activation, using an inert DuoBody® format.

    Clinical Trials

    A Phase 1/2 clinical study of DuoBody®-CD40 x4-1BB in solid tumors is ongoing.

    More info

  • DuoHexaBody®-CD37 (GEN3009)

    Partnership: AbbVie

    Target: CD37

    Hematological malignancies:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    DuoHexaBody®-CD37 (GEN3009) is a bispecific IgG1 antibody created with Genmab’s proprietary DuoHexaBody® technology platform, jointly owned by Genmab and AbbVie. The DuoHexaBody® platform combines the dual targeting of our DuoBody® technology with the enhanced potency of our HexaBody® technology, creating bispecific antibodies with target-mediated enhanced hexamerization. In preclinical settings, DuoHexaBody®-CD37 has been shown to induce potent in vivo and in vitro anti-tumor activity.

    Clinical Trials

    A Phase 1 clinical study of DuoHexaBody®-CD37 in hematological malignancies is ongoing.

    More info

Partner-owned products incorporating Genmab’s innovation

  • Ofatumumab

    Partnership: Novartis Pharma AG.

    Target: CD20

    Relapsing multiple sclerosis:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Ofatumumab is a human monoclonal antibody which targets an epitope in the CD20 molecule encompassing parts of the small and large extracellular loops.

    Clinical Studies

    A subcutaneous formulation of ofatumumab is being investigated for use in relapsing multiple sclerosis (RMS). Ofatumumab is being studied in clinical trials, including Investigator Sponsored Studies.

    More info

  • Camidanlumab tesirine

    Partnership: ADC Therapeutics

    Target: CD25

    Relapsed or refractory Hodgkin lymphoma:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Camidanlumab tesirine (ADCT-301) is an antibody-drug conjugate (ADC) combining Genmab’s HuMax®-TAC antibody and ADC Therapeutics’ PBD-based warhead and linker technology. Camidanlumab tesirine targets CD25, which is expressed on a variety of hematological tumors and shows limited expression on normal tissues, except for regulatory T cells (Tregs), which are known to be immunosuppressive.

    Clinical Trials

    A Phase 2 study of camidanlumab tesirine to treat relapsed or refractory Hodgkin lymphoma is ongoing. Camidanlumab tesirine is also being tested in a Phase 1b in multiple solid tumors.

    More info

  • Mim8

    Partnership: Novo Nordisk

    Target: FIXa, FX

    Haemophilia A:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Mim8 is a novel, next-generation factor VIII mimetic human bispecific antibody. Mim8 is a highly potent molecule bridging factor IXa (FIXa) and factor X (FX) in development for subcutaneous treatment of people with haemophilia A.

    Clinical Trials

    Mim8 is being investigated in a clinical study in healthy subjects and subjects with haemophilia A.

    More info

  • Amivantamab (JNJ-61186372)

    Partnership: Janssen Biotech, Inc.

    Target: EGFR, cMet

    Non-small-cell lung cancer:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Amivantamab (JNJ-61186372) is a bispecific antibody that targets EGFR and cMet, two validated cancer targets. The two antibodies used to create amivantamab (JNJ-61186372) were both created by Genmab.

    Clinical Trials

    Amivantamab (JNJ-61186372) is being investigated in a Phase 2 clinical study to treat non-small-cell lung cancer (NSCLC).

    More info

  • JNJ-63709178

    Partnership: Janssen Biotech, Inc.

    Target: CD123, CD3

    Acute Myeloid Leukemia:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    JNJ-63709178 is a bispecific antibody that targets CD3, which is expressed on T-cells and CD123, which is overexpressed in various hematologic malignancies. JNJ-63709178 can redirect T-cells, resulting in T-cell mediated killing of CD123 positive acute myeloid leukemia (AML) cells.

    Clinical Trials

    JNJ-63709178 is being investigated in acute myeloid leukemia.

    More info

  • Teclistamab (JNJ-64007957)

    Partnership: Janssen Biotech, Inc.

    Target: BCMA, CD3

    Relapsed or refractory multiple myeloma:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Teclistamab (JNJ-64007957) is a bispecific antibody that targets CD3, which is expressed on T-cells and BCMA, which is expressed in mature B lymphocytes.

    Clinical Trials

    Teclistamab (JNJ-64007957) is being investigated in a Phase 1 clinical study to treat relapsed or refractory multiple myeloma.

    More info

  • Talquetamab (JNJ-64407564)

    Partnership: Janssen Biotech, Inc.

    Target: GPRC5D, CD3

    Relapsed or refractory multiple myeloma:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Talquetamab (JNJ-64407564) is a bispecific antibody that targets CD3, which is expressed on T-cells, and GPRC5D, which is highly expressed in multiple myeloma cells.

    Clinical Trials

    Talquetamab (JNJ-64407564) is being investigated in a Phase 1 clinical study to treat relapsed or refractory multiple myeloma.

    More info

  • JNJ-67571244

    Partnership: Janssen Biotech, Inc.

    Target: CD33, CD3

    Relapsed or refractory acute myeloma leukemia or myelodysplastic syndrome:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    JNJ-67571244 is a bispecific antibody that targets CD3, which is expressed on T-cells and CD33, which is frequently expressed in acute myeloma leukemia (AML) and myelodysplastic syndrome (MDS).

    Clinical Trials

    JNJ-67571244 is being investigated in a Phase 1 clinical study to treat relapsed or refractory AML or MDS.

    More info

  • JNJ-63898081

    Partnership: Janssen Biotech, Inc.

    Target: PSMA, CD3

    Solid tumors:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    JNJ-63898081 is a bispecific antibody that targets CD3, which is expressed on T-cells, and prostate- specific membrane antigen (PSMA), which is highly expressed on prostate adenocarcinomas.

    Clinical Trials

    JNJ-63898081 is being investigated in a Phase 1 clinical study to treat advanced solid tumors.

    More info

  • HuMax®-IL8

    Partnership: Bristol-Myers Squibb Company

    Target: IL8

    Advanced cancers:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    HuMax®-IL8 is a high affinity, fully human antibody directed towards IL-8. IL-8 has been shown to be involved in several aspects of tumor development, including tumor spread (metastasis), cancer stem cell renewal and tumor immunosuppression. HuMax®-IL8 has been shown to inhibit these processes and to inhibit tumor growth in pre-clinical tumor models. HuMax®-IL8 is in development for the treatment of advanced cancers under an agreement with Bristol-Myers Squibb Company.

    Clinical Trials

    HuMax®-IL8 is in development in advanced cancers.

    More info

  • Lu AF82422

    Partnership: Lundbeck

    Target: alpha-Synuclein

    Parkinson’s disease:

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

    Overview

    Lu AF82422 is a human antibody that targets alpha-synuclein, a protein that is linked to Parkinson’s disease. Lu AF82422 targets the underlying biology of Parkinson’s disease and aims to treat the disease by slowing or stopping the disease progression.

    Clinical Trials

    Lu AF82422 is being investigated in a Phase 1 clinical study in healthy volunteers and patients with Parkinson’s disease.

    More info

  • ~20 active pre-clinical programs

    Partnership: 

    Target: 

    Partnered & proprietary programs (HuMab, DuoBody®, DuoHexaBody® and HexaBody®):

    • Pre-clinical
    • 1
    • 1/2
    • 2
    • 3

Out-licensed products marketed by partner

Tisotumab vedotin – 50:50 partnership with Seattle Genetics; DuoBody-PD-L1x4-1BB and DuoBody-CD40x4-1BB – 50:50 partnership with BioNTech; Epcoritamab and DuoHexaBody-CD37 – 50:50 partnership with AbbVie

Products under development by a third-party incorporating Genmab technology and innovation

  • Putting our expertise to work

    See how we put our in-depth knowledge of antibody biology into action

    Learn about our science

  • Innovation for the future

    Leveraging technologies to create first- or best-in-class products

    See our technologies

  • Partners in science

    See how our collaborative spirit drives our partnerships

    See current partners

You are now leaving Genmab.com to go to our collaborator’s website. If you continue, we encourage you to read the website’s privacy and cookie policy.